Abstract: The present invention relates to novel modified proteins having N-terminal free thiols that can be produced by recombinant methods and are ready for further chemical derivatization. In particular, the invention relates to erythropoietin conjugate compounds having altered biochemical, physiochemical and pharmacokinetic properties.

Abstract: This invention describes a method for removing unreacted activated lipid moieties using a bifunctional ligand containing a first functional group reactive with the activating group of the lipid and a second functional group capable of binding to an affinity reagent or support. These reagents can be used to quench reactions between peptides/proteins and other moieties such as activated PEGs or lipids. Once the reaction has been quenched, the reaction mixture can be passed over an affinity column that will bind the peptide, biotin or other ligand attached to the “quenched” reagent and thereby remove it from the reaction mixture.

Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule to a non-antigenic hydrophilic polymer that can also be covalently linked to an organic molecule either of which modification increases the circulating serum half-life of the composition.

Abstract: The present invention provides methods of preparing and identifying antibodies against a loop domain of a protein, such as an extracellular loop (ECL) domain of a transmembrane protein. Cyclic and end-to-end cyclized peptides corresponding to loop domains are employed in the present invention. Transmembrane proteins contemplated by the invention include the G-coupled protein receptor or a viral envelope protein.

Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule to a non-antigenic hydrophilic polymer that can also be covalently linked to an organic molecule either of which modification increases the circulating serum half-life of the composition.

Abstract: The present invention relates to novel modified proteins having N-terminal free thiols that can be produced by recombinant methods and are ready for further chemical derivatization. In particular, the invention relates to erythropoietin conjugate compounds having altered biochemical, physiochemical and pharmacokinetic properties.

Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule to a non-antigenic hydrophilic polymer that can also be covalently linked to an organic molecule either of which modification increases the circulating serum half-life of the composition.